Stryker (SYK) Panoramica del titolo
Stryker Corporation opera come azienda di tecnologia medica negli Stati Uniti e a livello internazionale. Maggiori dettagli
| Punteggio fiocco di neve | |
|---|---|
| Valutazione | 2/6 |
| Crescita futura | 2/6 |
| Prestazioni passate | 5/6 |
| Salute finanziaria | 4/6 |
| Dividendi | 4/6 |
Premi
Analisi del rischio
SYK Community Fair Values
Create NarrativeSee what 99 others think this stock is worth. Follow their fair value or set your own to get alerts.
Analyst Price Targets
Top Community Narratives
US$323.52
FV
5.8% sottovalutato sconto intrinseco6.00%
Revenue growth p.a.
376
users have viewed this narrative5users have liked this narrative
0users have commented on this narrative
8users have followed this narrative
Concorrenti di Stryker Corporation
Storia dei prezzi e prestazioni
| Prezzi storici delle azioni | |
|---|---|
| Prezzo attuale dell'azione | US$304.69 |
| Massimo di 52 settimane | US$404.87 |
| Minimo di 52 settimane | US$281.00 |
| Beta | 0.78 |
| Variazione di 1 mese | -3.73% |
| Variazione a 3 mesi | -7.25% |
| Variazione di 1 anno | -19.64% |
| Variazione a 3 anni | 2.64% |
| Variazione a 5 anni | 17.03% |
| Variazione dall'IPO | 56,150.43% |
Notizie e aggiornamenti recenti
Recent updates
Aggiornamento della narrazione • Jun 14
SYK: Hospital Digitization And Cyber Resilience Will Support 2026 Recovery Prospects
Stryker's fair value estimate has been adjusted slightly lower to $386.80 from $389.24 as analysts temper price targets in response to lower utilization expectations, inflation headwinds, and more conservative long term margin and P/E assumptions. Analyst Commentary Recent Street research on Stryker has been active, with most updates focused on resetting price targets and reassessing long term assumptions around utilization, inflation, and margins.Aggiornamento della narrazione • May 31
SYK: Hospital Digitization And Cyber Resilience Will Drive 2026 Rebound Potential
Analysts have trimmed Stryker's updated price target slightly, reflecting a minor change of about $0.11 and combining a series of recent target cuts from multiple firms with one modest increase, as they reassess assumptions around discount rate, revenue growth, profit margin, and future P/E. Analyst Commentary Bullish Takeaways Bullish analysts who recently raised or affirmed higher targets highlight what they see as healthy fundamentals in U.S. medical technology, which they argue can support Stryker's growth assumptions that underpin current P/E expectations.Seeking Alpha • May 27
Stryker: Reaching Interesting Levels
Summary Stryker shares have declined 10% since March amid a soft Q1 and cybersecurity concerns, but full-year guidance remains intact. Q1 organic sales growth slowed to 2.4% due to a cyber incident, but management expects 8.0-9.5% organic growth for the full year. Stryker´s bolt-on acquisition of Amplitude Vascular Systems expands cardiovascular exposure, with leverage still manageable at around 2x EBITDA. Valuation has compressed to 20-21x earnings, making current levels more attractive as recovery and guidance reaffirmation signal resilience. Read the full article on Seeking AlphaAggiornamento della narrazione • May 14
SYK: Hospital Digitization And Cyber Resilience Will Support 2026 Upside
Analysts have nudged Stryker's fair value estimate lower to about $389 from roughly $419, as a wave of reduced price targets led by firms like Truist, Barclays and others has been paired with updated assumptions for slightly lower future P/E multiples, alongside higher projected revenue growth and profit margins. Analyst Commentary Recent research around Stryker has tilted more cautious, with a cluster of reduced price targets across multiple firms, offset by a smaller group of more supportive views.Articolo di analisi • May 04
Stryker Corporation Just Missed Earnings - But Analysts Have Updated Their Models
As you might know, Stryker Corporation ( NYSE:SYK ) last week released its latest first-quarter, and things did not...Aggiornamento della narrazione • Apr 21
SYK: Diversified Portfolio And Hospital Digitization Will Support 2026 Upside
Analysts have trimmed Stryker's fair value estimate by about $6 to $419, reflecting slightly higher discount rate assumptions, a modestly lower revenue growth outlook, and a slightly lower future P/E multiple, even as profit margin expectations are marginally higher. Analyst Commentary Recent Street research on Stryker shows a mix of optimism about the company’s long term growth drivers and caution around near term valuation and risk.Aggiornamento della narrazione • Apr 06
SYK: Diversified Growth Drivers And Robotics Adoption Will Support 2026 Upside
The updated analyst price target for Stryker edges slightly higher to about $425 per share, as analysts balance recent target trims with continued support from firms highlighting a healthy U.S. medtech backdrop, diversified growth drivers, and potential near term catalysts. Analyst Commentary Recent research paints a mixed but generally constructive picture for Stryker, with several firms adjusting price targets and ratings as they reassess growth drivers, execution, and valuation against a still supportive U.S. medtech backdrop.Aggiornamento della narrazione • Mar 22
SYK: Diversified Portfolio And Robotics Adoption Will Support 2026 Upside
Analysts have trimmed the Stryker fair value estimate by less than $1 to about $424 per share, reflecting a slightly higher discount rate and a modestly lower assumed future P/E multiple. Recent research cites mixed price target moves and differing views on near term catalysts and sector trends.Aggiornamento della narrazione • Mar 07
SYK: Diversified Product Reach And Robotics Expansion Will Support 2026 Upside
The analyst fair value estimate for Stryker has edged up by about $0.50 to $424.90, as analysts factor in recent price target moves, including several Outperform ratings that highlight the company's broader product reach and diversified growth profile. Analyst Commentary Recent research on Stryker reflects a mix of optimism about the company’s growth profile and some caution on valuation and sector level risks.Aggiornamento della narrazione • Feb 20
SYK: Diversified Medtech Portfolio And Robotics Execution Will Support 2026 Upside
Analysts made a modest trim to their blended Stryker price target, reflecting mixed recent revisions that range from higher targets up to $465 with Outperform ratings to lower targets near $390 and $399 with a Hold rating, as they weigh the company's broader product reach and expected sales and earnings trends against valuation and sector-level risks. Analyst Commentary Recent research on Stryker reflects a split view, with some analysts leaning into the growth story and others more guarded on valuation and sector risks.Articolo di analisi • Feb 09
Stryker's (NYSE:SYK) Earnings Seem To Be Promising
Stryker Corporation's ( NYSE:SYK ) recent earnings report didn't offer any surprises, with the shares unchanged over...Articolo di analisi • Feb 07
Stryker (NYSE:SYK) Is Due To Pay A Dividend Of $0.88
Stryker Corporation ( NYSE:SYK ) will pay a dividend of $0.88 on the 30th of April. This takes the annual payment to...Aggiornamento della narrazione • Feb 06
SYK: Orthopedics And Robotics Execution Will Support 2026 Rebound In Medtech Sentiment
Analysts have reduced their fair value estimate for Stryker by about $3 to $424, reflecting slightly softer revenue growth assumptions, a future P/E multiple closer to 34, and a modestly higher profit margin outlook following recent mixed price target changes across Wall Street. Analyst Commentary Recent research coverage on Stryker reflects a mix of optimism and caution, with several firms adjusting price targets and ratings in different directions.Aggiornamento della narrazione • Jan 22
SYK: Orthopedics And Robotics Execution Will Support 2026 Upside Potential
Analysts have inched their average price target on Stryker higher, with a modest fair value lift to about US$427.40, as they weigh mixed target changes across firms against ongoing views that the company remains a high quality large-cap MedTech name heading into 2026. Analyst Commentary Recent Street research on Stryker shows a split tape, with several firms lifting targets and ratings while others trim fair values or stay neutral.Aggiornamento della narrazione • Jan 08
SYK: Orthopedics Strength And Robotics Adoption Will Support Long-Term Upside
Narrative Update: Stryker The analyst price target for Stryker has been adjusted slightly lower to reflect a fair value estimate of about $427.22. Analysts point to mixed but generally solid recent research that highlights compressed forward multiples, updated targets in the $390 to $453 range, and ongoing views of Stryker as a high quality large cap MedTech name, with attractive entry points and healthy procedure and CapEx trends into 2026.Aggiornamento della narrazione • Dec 19
SYK: Expanding Orthopedics And Robotics Footprint Will Drive Long-Term Upside Potential
Analysts have modestly trimmed our fair value estimate for Stryker to approximately $428 from about $433 per share, reflecting a slightly higher discount rate and lower valuation multiple, even as they acknowledge improving revenue growth, rising profit margins, and continued operating leverage highlighted in recent research updates and investor day commentary. Analyst Commentary Street research on Stryker has been active in recent weeks, with modestly higher and lower price targets reflecting a balanced mix of optimism on execution and caution on MedTech sentiment and relative growth.Articolo di analisi • Dec 14
Stryker (NYSE:SYK) Has Announced That It Will Be Increasing Its Dividend To $0.88
Stryker Corporation's ( NYSE:SYK ) periodic dividend will be increasing on the 30th of January to $0.88, with investors...Articolo di analisi • Sep 08
Does Stryker (NYSE:SYK) Have A Healthy Balance Sheet?
Legendary fund manager Li Lu (who Charlie Munger backed) once said, 'The biggest investment risk is not the volatility...Articolo di analisi • Aug 08
Investors Can Find Comfort In Stryker's (NYSE:SYK) Earnings Quality
NYSE:SYK 1 Year Share Price vs Fair Value Explore Stryker's Fair Values from the Community and select yours The most...Articolo di analisi • Jul 09
Estimating The Intrinsic Value Of Stryker Corporation (NYSE:SYK)
Key Insights Using the 2 Stage Free Cash Flow to Equity, Stryker fair value estimate is US$371 With US$390 share price...Rendimenti per gli azionisti
| SYK | US Medical Equipment | US Mercato | |
|---|---|---|---|
| 7D | -1.1% | -2.7% | -1.8% |
| 1Y | -19.6% | -22.1% | 23.3% |
Ritorno vs Industria: SYK ha superato il US Medical Equipment che ha restituito -22.1 % nell'ultimo anno.
Rendimento vs Mercato: SYK ha avuto una performance inferiore al mercato US che ha registrato un rendimento 23.3 % nell'ultimo anno.
Volatilità dei prezzi
| SYK volatility | |
|---|---|
| SYK Average Weekly Movement | 4.2% |
| Medical Equipment Industry Average Movement | 8.8% |
| Market Average Movement | 7.3% |
| 10% most volatile stocks in US Market | 16.8% |
| 10% least volatile stocks in US Market | 3.1% |
Prezzo delle azioni stabile: SYK non ha avuto una volatilità dei prezzi significativa negli ultimi 3 mesi rispetto al mercato US.
Volatilità nel tempo: La volatilità settimanale ( 4% ) di SYK è rimasta stabile nell'ultimo anno.
Informazioni sull'azienda
| Fondato | I dipendenti | AMMINISTRATORE DELEGATO | Sito web |
|---|---|---|---|
| 1941 | 56,000 | Kevin Lobo | www.stryker.com |
Stryker Corporation opera come società di tecnologia medica negli Stati Uniti e a livello internazionale. Opera attraverso due segmenti, MedSurg e Neurotechnology e Orthopaedics. Il segmento MedSurg and Neurotechnology offre attrezzature chirurgiche, tecnologie per la sicurezza del paziente e dell'operatore, sistemi di navigazione, sistemi endoscopici e di comunicazione, prodotti per la movimentazione dei pazienti, attrezzature mediche di emergenza e prodotti monouso per la terapia intensiva, tecnologie per la comunicazione clinica e piattaforme di assistenza virtuale assistite dall'intelligenza artificiale, prodotti minimamente invasivi per il trattamento dell'ictus ischemico ed emorragico acuto e del tromboembolismo venoso, prodotti per le procedure chirurgiche cerebrali tradizionali e per quelle a cranio aperto, e prodotti per l'orthobiologic e la biosurgery, tra cui innesti ossei sintetici e prodotti per l'aumento vertebrale.
Stryker Corporation Riepilogo dei fondamenti
| SYK statistiche fondamentali | |
|---|---|
| Capitalizzazione di mercato | US$118.00b |
| Utili (TTM) | US$3.34b |
| Ricavi(TTM) | US$25.27b |
35.0x
Rapporto P/E4.6x
Rapporto P/SSYK è sopravvalutato?
Vedi Fair Value e analisi di valutazioneUtili e ricavi
| SYK Conto economico (TTM) | |
|---|---|
| Ricavi | US$25.27b |
| Costo del fatturato | US$8.92b |
| Profitto lordo | US$16.35b |
| Altre spese | US$13.01b |
| Utili | US$3.34b |
Ultimi utili riportati
Mar 31, 2026
Prossima data di guadagno
n/a
| Utile per azione (EPS) | 8.70 |
| Margine lordo | 64.70% |
| Margine di profitto netto | 13.21% |
| Rapporto debito/patrimonio netto | 64.1% |
Come si è comportato SYK nel lungo periodo?
Vedi performance storica e confrontoDividendi
1.2%
Rendimento attuale del dividendo39%
Rapporto di remunerazioneSYK paga dividendi affidabili?
Vedere la storia dei dividendi e i benchmark di SYK| Stryker date dei dividendi | |
|---|---|
| Data di stacco del dividendo | Jun 30 2026 |
| Data di pagamento dei dividendi | Jul 31 2026 |
| Giorni fino al dividendo Ex | 6 days |
| Giorni prima della data di pagamento dei dividendi | 37 days |
SYK paga dividendi affidabili?
Vedere la storia dei dividendi e i benchmark di SYKAnalisi aziendale e situazione dei dati finanziari
| Dati | Ultimo aggiornamento (ora UTC) |
|---|---|
| Analisi dell'azienda | 2026/06/22 14:18 |
| Prezzo dell'azione a fine giornata | 2026/06/22 00:00 |
| Utili | 2026/03/31 |
| Utili annuali | 2025/12/31 |
Fonti dei dati
I dati utilizzati nella nostra analisi aziendale provengono da S&P Global Market Intelligence LLC. I seguenti dati sono utilizzati nel nostro modello di analisi per generare questo report. I dati sono normalizzati, il che può comportare un ritardo nella disponibilità della fonte.
| Pacchetto | Dati | Tempistica | Esempio Fonte USA * |
|---|---|---|---|
| Dati finanziari della società | 10 anni |
| |
| Stime di consenso degli analisti | +3 anni |
|
|
| Prezzi di mercato | 30 anni |
| |
| Proprietà | 10 anni |
| |
| Gestione | 10 anni |
| |
| Sviluppi principali | 10 anni |
|
* Esempio per i titoli statunitensi, per i titoli non statunitensi si utilizzano forme e fonti normative equivalenti.
Se non specificato, tutti i dati finanziari si basano su un periodo annuale ma vengono aggiornati trimestralmente. Si tratta dei cosiddetti dati TTM (Trailing Twelve Month) o LTM (Last Twelve Month). Per saperne di più.
Modello di analisi e Snowflake
I dettagli del modello di analisi utilizzato per generare questo report sono disponibili sulla nostra pagina Github; disponiamo inoltre di guide su come utilizzare i nostri report e di tutorial su Youtube.
Scoprite il team di livello mondiale che ha progettato e realizzato il modello di analisi Simply Wall St.
Metriche di settore e industriali
Le nostre metriche di settore e di sezione sono calcolate ogni 6 ore da Simply Wall St; i dettagli del nostro processo sono disponibili su Github.
Fonti analitiche
Stryker Corporation è coperta da 53 analisti. 26 di questi analisti ha fornito le stime di fatturato o di utile utilizzate come input per il nostro report. Le stime degli analisti vengono aggiornate nel corso della giornata.
| Analista | Istituzione |
|---|---|
| David Toung | Argus Research Company |
| Jeffrey Johnson | Baird |
| Adam Feinstein | Barclays |